Jackpot Digital Goes Live at Treasure Island Resort & Casino in Minnesota
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2025) - Jackpot Digital Inc. (TSXV: JJ) (TSXV: JJ.WT.C) (OTCQB: JPOTF) (Frankfurt Stock Exchange: LVH3) (the "Company" or "Jackpot Digital"), the leading provider of dealerless electronic poker tables to the global gaming industry, is pleased to announce the successful installation of its Jackpot Blitz® dealerless poker electronic table game ("ETG") at Treasure Island Resort & Casino, located in Welch, Minnesota, U.S.A.
Jackpot Blitz® is an advanced, automated casino poker table that eliminates the need for traditional dealers, allowing for a faster, more efficient gaming experience while maintaining a high level of player engagement. The installation at Treasure Island Resort & Casino is the latest in a series of successful deployments that highlight the growing interest in Jackpot Digital's dealerless poker tables.
Treasure Island Casino Operations Director, Michael Jankoviak, states, "We aim to be the premier casino destination, crafting unforgettable moments through exceptional guest experiences and a vibrant atmosphere brimming with the latest gaming innovations and thrilling entertainment. Jackpot Blitz® is one of these cutting-edge offerings that our guests can experience."
The installation is part of Jackpot Digital's continued efforts to expand its footprint in the land-based casino gaming industry, with a focus on enhancing the customer experience through innovative and engaging dealerless poker ETGs. The Company is committed to driving growth by meeting the evolving needs of casino operators and players alike.
In addition to Jackpot's cruise ship customers, which include Carnival Cruises, Princess Cruises, Holland America, AIDA, and Costa Cruises, Jackpot has announced land-based installations or orders in Canada and the United States, including California, Louisiana, Michigan, Minnesota, Mississippi, Montana, New Mexico, New York, Oregon, Quebec, Saskatchewan, U.S. Virgin Islands, as well as several international jurisdictions.
To view a short video of Jackpot Brand Ambassador, Pro Football Hall of Fame and Super Bowl winning coach, Jimmy Johnson, sharing the advantages of the world leading Jackpot Blitz®, click the thumbnail below:
Cannot view this video? Visit:https://www.youtube.com/watch?v=Ok313WD5NpI
About Jackpot Digital Inc.
A positive disruptor in the casino business, Jackpot Digital Inc. is a leading provider of electronic poker table games, offering innovative gaming solutions to casinos worldwide. The Company specializes in the development and deployment of dealerless multiplayer electronic poker ETGs, providing operators with efficient, cost-effective, and revenue-generating alternatives to traditional live-dealer table games. Jackpot Digital is committed to enhancing the player experience and helping operators optimize their gaming offerings.
About Treasure Island Resort & Casino
Located along the Mississippi River, Treasure Island Resort & Casino boasts fine and casual dining options, a full-service salon and spa, a family friendly water park, bowling alley, an event center and live entertainment venues including an outdoor amphitheater. Treasure Island's 788-room hotel is the second largest in Minnesota.
Treasure Island's action-packed gaming floor features thousands of slots, rows upon rows of table games and a bingo hall. Seasonal amenities include a marina, 100-passenger cruise yacht, an RV park and golf course.
For more information on the Company, please contact Jake H. Kalpakian, President and CEO, at (604) 681- 0204 ext. 6105, or visit the Company's website at www.jackpotdigital.com.
On behalf of the Board of Jackpot Digital Inc.
"Jake H. Kalpakian"
_____________________________ Jake H. KalpakianPresident & CEO
Trading in the securities of the Company should be considered speculative. The TSX Venture Exchange has neither approved nor disapproved the contents of this news release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. Certain statements contained herein are "forward-looking". Forward-looking statements may include, among others, statements regarding Jackpot's future plans, the obtaining of customary regulatory approvals, projected or proposed financings, costs, objectives, economic or technical performance, or the assumptions underlying any of the foregoing. In this News Release, words such as "may", "would", "could", "will", "likely", "enable", "feel", "seek", "project", "predict", "potential", "should", "might", "objective", "believe", "expects", "propose", "anticipate", "intend", "plan", "plans" "estimate", "in due course" and similar words are used to identify forward-looking statements. Forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those expressed or implied. Although management believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, projections and estimations, there can be no assurance that these assumptions, projections or estimations are accurate. Readers, shareholders and investors are therefore cautioned not to place reliance on any forward-looking statements as the plans, assumptions, intentions or expectations upon which they are based might not occur.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255776
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
3 hours ago
- Bloomberg
Thailand Bars Citizens From Crossing to Cambodia Casino City
Thailand banned its citizens from going to work in a casino city in Cambodia, the latest curb on border movements as tensions simmer between the two Southeast Asian neighbors. All Thais who are employed in casinos, gambling dens and other entertainment venues in Poipet are barred from leaving Thailand via checkpoints in Sa Kaeo province from Tuesday morning, according to a statement from the Royal Thai Army, which cited safety reasons.
Business Wire
4 hours ago
- Business Wire
Volt Lithium Announces Shareholder Approval of Name Change and Results of Its 2025 Annual and Special Meeting
CALGARY, Alberta--(BUSINESS WIRE)--Volt Lithium Corp. (TSXV: VLT) (the ' Company ') is pleased to announce that shareholders approved the company name change to 'LibertyStream Infrastructure Partners Inc.' (the ' Name Change ') at the annual and special meeting of shareholders of the Company held today, June 18, 2025 (the ' Meeting '). The Name Change and rebrand was proposed as part of the Company's ongoing strategy to partner with key oilfield infrastructure players in the US to extract lithium, a valuable critical mineral, from the significant streams of produced water associated with oil and gas production. The Company has filed with the TSX Venture Exchange (the ' TSXV ') a notice of name change to 'LibertyStream Infrastructure Partners Inc.' As part of the Name Change, once required regulatory approvals are provided, the Company will commence trading on the TSXV under the new symbol 'LIB'. The Company will advise the market of the new trading date and confirmed symbol once advised by the TSXV. In addition to the Name Change, the Company is pleased to announce that each other item of business placed before the shareholders, and as outlined in the management information circular of the Company dated May 9, 2025, was approved at the Meeting, being the re-election of each of Andrew Leslie, Alex Wylie, Martin Scase, Kyle Hookey, and Warner Uhl as directors of the Company, the appointment of De Visser Gray LLP, Chartered Professional Accountants, as auditors of the Company and the re-approval of each of the stock option plan and omnibus incentive plan of the Company. Upcoming Investor Webinar (June 19, 2025): The Company will host a live 'Ask-Me-Anything' webinar with President & Chief Executive Officer Alex Wylie on . Shareholders and other interested parties can register in advance and submit questions at: A replay will be made available online following the event. About the Company The Company is a lithium development and technology company aiming to be one of North America's first commercial producers of lithium carbonates from oilfield brine. Our strategy is to generate value for shareholders by leveraging management's hydrocarbon experience and existing infrastructure to extract lithium deposits from existing wells, thereby reducing capital costs, lowering risks and supporting the world's clean energy transition. With four differentiating pillars, and a proprietary Direct Lithium Extraction (' DLE ') technology and process, the Company's innovative approach to development is focused on generating the highest lithium recoveries with lowest costs, positioning us for future commercialization. We are committed to operating efficiently and with transparency across all areas of the business staying sharply focused on creating long-term, sustainable shareholder value. Investors and/or other interested parties may sign up for updates about the Company's continued progress on its website: Forward-Looking Statements This news release includes certain 'forward-looking statements' and 'forward-looking information' within the meaning of applicable Canadian securities laws. When used in this news release, the words 'anticipate', 'believe', 'estimate', 'expect', 'target', 'plan', 'forecast', 'may', 'would', 'could', 'schedule' and similar words or expressions, identify forward-looking statements or information. Statements, other than statements of historical fact, may constitute forward looking information and include, without limitation, statements about the new trading symbol and receipt of regulatory approvals in respect of the Name Change; and general business and economic conditions. With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies and may prove to be incorrect. Forward-looking statements or information are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the delay or failure to receive regulatory or other approvals in respect of the Name Change. Many of these risks and uncertainties and additional risk factors generally applicable to the Company are described in the Company's annual information form for the year ended June 30, 2024 and its (final) short form base shelf prospectus dated July 20, 2023, each of which are available under the Company's profile at All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Business Wire
6 hours ago
- Business Wire
Satellos Bioscience Shareholders Elect Two New Board Members
TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (' Satellos ' or the ' Company '), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced the election of Iris Loew-Friedrich, M.D., Ph.D., and Selwyn Ho, MBBS, to its Board of Directors. 'I am so excited to welcome Dr. Loew-Friedrich and Dr. Ho to our Board at this pivotal time,' said Frank Gleeson, Satellos co-founder and CEO. 'We believe their deep expertise in global clinical and commercial development will be invaluable to Satellos as we advance SAT-3247 and realize our technology's transformative potential for the treatment of people living with Duchenne muscular dystrophy and other degenerative conditions. We look forward to drawing on their proven expertise in positioning Satellos for future partnerships and development strategies focused on delivering optimal value for shareholders.' A highly accomplished biotech and pharmaceutical executive, Dr. Loew-Friedrich is recognized as the senior clinical leader who shaped UCB into a global powerhouse in neurology and immunology. Serving as executive vice president and chief medical officer until 2024, she led UCB's worldwide development and regulatory strategy for over two decades, overseeing the global approvals of multiple blockbuster therapies, including Cimzia, Briviact, Evenity, Rystiggo, Zilbrysq, and Bimzelx. Her leadership was instrumental in advancing both common and rare disease treatments, with a deep and sustained commitment to improving outcomes for underserved patient populations. Prior to UCB, Loew-Friedrich held senior R&D roles at Schwarz Pharma, BASF Pharma, and Hoechst/Aventis, where she contributed to the development and success of market-leading drugs such as Humira, Arava, Actonel, Vimpat, and Neupro. Dr. Ho is a seasoned pharmaceutical and biotech executive with broad leadership experience across commercial strategy, business development, financing, and board governance. He has held senior roles at global companies including Dermira (Eli Lilly), UCB, Allergan (AbbVie), Novartis, and AstraZeneca, with expertise spanning ophthalmology, immunology, oncology, and dermatology. As CEO of Medigene AG, he led a strategic transformation and established and extended key partnerships with BioNTech, Regeneron, WuXi Biologics and EpimAb Biotherapeutics. Previously, as EVP & chief business officer at Connect Biopharma, he was instrumental in raising over $350 million through IPO and private funding. He also serves on the boards of Antennova Inc. and Peptomyc S.L., and as executive-in-residence at New Rhein Healthcare Investors. As part of the Annual General Meeting, Rima Al-awar, Ph.D., William Jarosz, J.D., and William McVicar, Ph.D., did not stand for reelection. 'I want to personally thank Rima, Bill and Bill for their dedicated service, thoughtful leadership and support,' said Gleeson. 'Their guidance helped position Satellos for continued progress, and we wish them all the best in their future endeavors.' About Satellos Bioscience Inc. Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit Notice on Forward-Looking Statements This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; and Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are 'forward-looking information or statements.' Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'believe', 'plan', 'expect', 'intend', 'estimate', 'anticipate', 'potential', 'prospective' , 'assert' or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the 'Risk Factors' section of Satellos' Annual Information Form dated March 26, 2025 (which is located on Satellos' profile at Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise. 530509798v.1
